JN-0413
Age-related cognitive decline
Pre-clinicalActive
Key Facts
About Jocasta Neuroscience
Jocasta Neuroscience is a private, pre-clinical biotech focused on harnessing the therapeutic potential of the Klotho protein for cognitive health. The company's approach is genetically validated, building on human genetic data showing that individuals with naturally higher Klotho levels exhibit better cognitive function and reduced risk of neurodegenerative diseases. Jocasta has raised a $35M Series A to advance its lead candidate, JN-0413, a subcutaneous formulation, with human trials estimated to begin in 2026. The company is led by a team of experts in cognitive health and longevity.
View full company profileOther Age-related cognitive decline Drugs
| Drug | Company | Phase |
|---|---|---|
| Centenara Vascular/Cognitive Program | Centenara Labs | Discovery |